Volume : 13, Issue : 09, September – 2026
Title:
DESIGN, OPTIMIZATION AND CHARACTERIZATION OF IVABRADINE CUBOSOMES FOR CONTROLLED DRUG DELIVERY
Authors :
Dr B Aparna*, Dr G Tulja Rani, T. Deekshitha Rama, K.Joysey, K.Divya Bharathi , H. Vasanth Kumar, Aakanksha Mishra
Abstract :
The present study was aimed at the formulation and evaluation of Ivabradine-loaded cubosomes for sustained drug delivery. Cubosomes are nanostructured lipid carriers that offer advantages such as high drug-loading capacity, controlled drug release, improved stability, and enhanced bioavailability. The objective of the study was to develop a stable cubosomal formulation of Ivabradine and evaluate its physicochemical characteristics and drug release behavior.Preformulation studies including organoleptic evaluation, solubility studies, melting point determination, calibration curve preparation, and Fourier Transform Infrared (FTIR) spectroscopy were carried out. FTIR studies confirmed the compatibility of Ivabradine with the selected excipients, indicating the absence of significant drug–excipient interactions. Ivabradine-loaded cubosomes were prepared by the top-down method using glyceryl monostearate as the lipid phase and Pluronic F127 as the stabilizer.The prepared formulations were evaluated for particle size, zeta potential, surface morphology, entrapment efficiency, and in vitro drug release. The particle size of the cubosomes ranged from 169 to 183 nm, while zeta potential values ranged from -25 to -30 mV, indicating good stability of the formulations. Entrapment efficiency was found to range between 79.80% and 85.92%. In vitro drug release studies demonstrated sustained release of Ivabradine over a period of 8 hours. Among all formulations, F4 showed the best performance with a particle size of 169 nm, zeta potential of -30 mV, entrapment efficiency of 85.92%, and cumulative drug release of 98.52%Stability studies conducted according to ICH guidelines revealed that the optimized formulation remained stable under various storage conditions, with no significant changes in drug release characteristics. The results indicate that the developed Ivabradine-loaded cubosomal formulation is a promising carrier system for sustained drug delivery and may improve therapeutic efficacy and patient compliance.
Keywords: Ivabradine, Cubosomes, Glyceryl Monooleate, Poloxamer 407, Entrapment Efficiency, Sustained Release, Nanocarrier System.
Cite This Article:
Please cite this article in press B Aparna et al., Design, Optimization And Characterization Of Ivabradine Cubosomes For Controlled Drug Delivery.,. Indo Am. J. P. Sci, 2026; 13(09).
REFERENCES:
1. Allen LV, Popovich NG, Ansel HC. Ansel’s Pharmaceutical Dosage Forms and Drug Delivery Systems. 10th ed. Philadelphia: Lippincott Williams & Wilkins; 2014.
2. Aulton ME, Taylor KMG. Aulton’s Pharmaceutics: The Design and Manufacture of Medicines. 5th ed. Elsevier; 2018.
3. Sinko PJ. Martin’s Physical Pharmacy and Pharmaceutical Sciences. 6th ed. Lippincott Williams & Wilkins; 2011.
4. Higuchi T. Mechanism of sustained-action medication. Theoretical analysis of rate of release of solid drugs dispersed in solid matrices. J Pharm Sci. 1963;52:1145–1149.
5. Korsmeyer RW, Gurny R, Doelker E, Buri P, Peppas NA. Mechanisms of solute release from porous hydrophilic polymers. Int J Pharm. 1983;15:25–35.
6. Larsson K. Cubic lipid–water phases: structures and biomembrane aspects. J Phys Chem. 1989;93:7304–7314.
7. Spicer PT. Cubosome processing industrial nanoparticles for advanced delivery. Curr Opin Colloid Interface Sci. 2005;10:274–279.
8. Shah MH, Paradkar A. Cubic liquid crystalline glyceryl monooleate matrices for oral delivery of enzyme. Int J Pharm. 2005;294:161–171.
9. Esposito E, Cortesi R, Drechsler M, et al. Cubosome dispersions as delivery systems for percutaneous administration of indomethacin. Pharm Res. 2005;22:2163–2173.
10. Boyd BJ, Whittaker DV, Khoo SM, Davey G. Lyotropic liquid crystalline phases formed from glycerate surfactants as sustained release drug delivery systems. Int J Pharm. 2006;309:218–226.
11. International Council for Harmonisation (ICH). ICH Q1A (R2): Stability Testing of New Drug Substances and Products. Geneva; 2003.
12. United States Pharmacopeia (USP). USP–NF. Rockville, MD: United States Pharmacopeial Convention.
13. British Pharmacopoeia Commission. British Pharmacopoeia. London: The Stationery Office.
14. Rang HP, Dale MM, Ritter JM, Flower RJ. Rang and Dale’s Pharmacology. 9th ed. Elsevier; 2020.
15. DrugBank Online. Ivabradine Hydrochloride Drug Profile.
16. Hanan M, et al. Cubosome nanoparticles for enhancement of intestinal drug release. Drug Dev Ind Pharm. 2018.